Visits: 3120, Avg visit time (secs): 235,72 Back to Index
| Page | Hits | Percent |
|---|---|---|
| 1577 | 50,54% | |
| /amylin/efsd-amylin-rfa09.html | 359 | 11,51% |
| /programmes.html | 309 | 9,90% |
| /home.html | 177 | 5,67% |
| /efsd-jdrf-novo/efsd-jdrf-novo-rfa09.html | 55 | 1,76% |
| /msd/albert-renold/efsd-msd-arenold.html | 50 | 1,60% |
| /novo-t2/efsd-novo-t2-rfa09.html | 45 | 1,44% |
| /amylin/efsd-amylin-rfa10.html | 41 | 1,31% |
| /lilly/programme/efsd-lilly-cds-fellowship09.html | 36 | 1,15% |
| /regulations.html | 34 | 1,09% |
| /lilly/programme/efsd-lilly-rfa09.html | 33 | 1,06% |
| Page | Hits | Percent |
|---|---|---|
| /exit.htm | 1615 | 51,76% |
| /programmes.html | 300 | 9,62% |
| /lifescan/efsd-lifescan-rfa09.html | 263 | 8,43% |
| /novo-t2/efsd-novo-t2-rfa09.html | 136 | 4,36% |
| /lilly/programme/efsd-lilly-rfa09.html | 114 | 3,65% |
| /home.html | 91 | 2,92% |
| /recipients.html | 65 | 2,08% |
| /efsd-jdrf-novo/efsd-jdrf-novo-rfa09.html | 55 | 1,76% |
| /msd/albert-renold/efsd-msd-arenold.html | 49 | 1,57% |
| /gsk/efsd-gsk-rfa09.html | 23 | 0,74% |
| /gsk/efsd-gsk-rfa08.html | 22 | 0,71% |